Novo Nordisk Faces a Fork in the Road as Pipeline Progress Meets Profit Pressure

Novo Nordisk stock trades 50% below peak amid GLP-1 competition from Eli Lilly's oral pill, regulatory wins, and a mixed technical outlook.

Novo Nordisk’s stock has been on a bruising ride, shedding more than 21% since January to trade at €35.12. That puts the Danish pharma giant roughly 50% below its 12-month peak, though a roughly 15% bounce from the March low offers a sliver of relief. The technical picture is mixed: the relative strength index hovers near 26, deep in oversold territory, while the share price has crept back above its 50-day moving average of €33.78 but remains well shy of the 200-day line at €42.67. Analysts at Traders Union see a sideways grind ahead, with no clear breakout catalyst in sight.

The company commands nearly 60% of the global GLP-1 therapy market by volume, according to its latest annual report, but that dominance is being tested. Management has guided for a currency-adjusted revenue decline of up to 13% in the current fiscal year, while the consensus among analysts points to a 16% drop in earnings per share. The forward price-to-earnings multiple sits at a modest 12.5, a far cry from the premium valuations the stock once commanded.

The Competitive Landscape Heats Up

Eli Lilly has emerged as the most immediate threat. Early this month, the US Food and Drug Administration approved “Foundayo” (orforglipron), an oral weight-loss pill that requires no food restrictions. The pricing is aggressive: between $149 and $349 per month for self-pay patients, undercutting Novo Nordisk’s injectable Wegovy. The new entrant marks the second oral GLP-1 option to hit the market, and Pfizer, following its acquisition of Metsera, is also ramping up its presence.

Novo Nordisk is not standing still. This month, it launched a high-dose version of Wegovy, branded Wegovy HD, in the US at roughly $399 per month. The company is betting that a stronger injectable formulation can hold its ground against the oral challengers. But the market remains skeptical: of the eight analyst ratings tracked, seven are “hold” and only one is “buy,” with a consensus price target of €43.

Regulatory Wins Offer a Counter-Narrative

On the pipeline front, there is genuine progress. The FDA has granted fast-track designation to Coramitug, a candidate for ATTR cardiomyopathy, a designation that accelerates development and review for serious conditions with unmet medical need. In Europe, Wegovy has become the first GLP-1 weight-loss drug approved for 48-hour delivery across the EU, a logistical upgrade that should simplify the supply chain.

Two other milestones are on the horizon. Oral semaglutide for type 2 diabetes is slated to launch in the second quarter of 2026, while the weight-loss candidate Amycretin is expected to transition from Phase II to Phase III trials. These developments could reshape the narrative if they deliver strong data.

A Parent Company Bet on Biohealth

Novo Holdings, the controlling shareholder, is making a strategic bet of its own, investing roughly $73 million into a South Korean private equity fund focused on biohealth. It is the firm’s first such commitment in Korea. While the move signals long-term confidence in the sector, it is unlikely to shift near-term sentiment around the stock.

The Bottom Line

Novo Nordisk enters a transitional year with a split-screen reality: a pipeline that is advancing and a core business that is shrinking. The next few months will test whether Wegovy HD can fend off Lilly’s oral pill and whether the launch of oral semaglutide in the second quarter can reignite growth. Until the revenue trend reverses, the stock lacks the fundamental catalyst for a sustained recovery.